Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement

BACKGROUND: ROS1 rearrangement is a novel molecular subgroup of non-small-cell lung cancer (NSCLC). This study aimed to investigate the efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement. RESULTS: A total of 2309 patients received ROS1 fusion d...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Zhang, Limin, Jiang, Tao, Zhao, Chao, Li, Wei, Li, Xuefei, Zhao, Sha, Liu, Xiaozhen, Jia, Yijun, Yang, Hui, Ren, Shengxiang, Zhou, Caicun
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2016
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342729/
https://ncbi.nlm.nih.gov/pubmed/27738334
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12612
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky